3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
14
Neoplasm Metastasis
5
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Pancreatic Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Digestive System Diseases
1
Cholangiocarcinoma
1
Carcinoma
1
Bile Duct Neoplasms
1
Advanced or Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Gemcitabine
14
Cisplatin
13
Capecitabine
11
Oxaliplatin
9
Fluorouracil
9
130-nm albumin-bound paclitaxel
9
Paclitaxel
8
pembrolizumab
7
Ramucirumab
6
Leucovorin
6
Carboplatin
6
Bevacizumab
6
Albumin-Bound Paclitaxel
6
Pemetrexed
4
Nivolumab
4
Irinotecan
4
Everolimus
4
Erlotinib Hydrochloride
4
Docetaxel
4
Cyclophosphamide
4
trastuzumab deruxtecan
3
Radiotherapy
3
Afatinib
3
zolbetuximab
2
pralsetinib
2
cabozantinib
2
Trastuzumab
2
Ipilimumab
2
vosaroxin
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma
×
trifluridine tipiracil drug combination
×
Clear all
NCT02921737
2021-02-04
UF-STO-PANC-003
University of Florida
Phase 2
Terminated
7 enrolled
12 charts